In one of the early-diagnosis cases of Spinal Muscular Atrophy (SMA), a rare genetic disorder that causes progressive muscle weakness, an infant diagnosed at just five weeks of age received gene replacement therapy at seven months. Early identification of the condition enabled doctors to initiate treatment promptly, offering the child a better opportunity to preserve motor function and achieve developmental milestones.